Based in Baugy (France) and Roma (Italy), ERBC provides all services from preclinical proof-of-concept to market of any type of drug candidate or chemical compound. Each project is managed by a study director, relying on a multi-disciplinary team of experts, notably in general pharmacology, cardiology, electrophysiology and pathophysiology, also benefiting from a world class academic and private network.
Every year, study reports from our two Centers are successfully used in support of market authorizations and new product approval submissions around the world, including the European (EMA, ECHA), US (FDA and EPA) and Japanese (MHLW and MAFF) regulatory authorities.
Investment in outstanding scientific and technical manpower, high-tech equipment and facilities are crucial cornerstones of our sound and organic growth. The quality and reliability of our performance are reflected by the many ongoing and long-lasting collaborations we maintain with leading international pharmaceutical and chemical companies.
ERBC is deeply engaged in animal ethics and welfare. ERBC supports the Basel Declaration, respects the 3Rs concept and continually improves its tools and procedures to maximize the balance between the benefit for health and the animal well-being.
The animal accommodation includes 4 independent units for separate housing of different species in an area of 5500 m2.
A fire-protected Archive was put into service in 2001. Elaborated and state-of-the-art protection systems and rigorous preventive maintenance and emergency procedures guarantee security from unforeseen external or internal hazards.
With 10,000 m2 surface, of which more than half is covered by laboratories and animal facilities, ERBC Italy includes independent units for separate housing of the different animal species.
Here also, security against external or internal risks is ensured by state-of-the-art protection systems as well as preventive and emergency maintenance procedures.